Last reviewed · How we verify
Reduced dose of DOAC
A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization.
A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.
At a glance
| Generic name | Reduced dose of DOAC |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | Direct Oral Anticoagulant (DOAC) |
| Target | Factor Xa or Factor IIa (thrombin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DOACs work by directly inhibiting Factor Xa or thrombin (Factor IIa) in the coagulation cascade, preventing the formation of blood clots. Dose reduction strategies aim to maintain therapeutic efficacy in specific patient populations (such as those with renal impairment, low body weight, or advanced age) while reducing the incidence of major bleeding complications. This phase 3 trial likely evaluates the safety and efficacy of reduced dosing regimens compared to standard dosing.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism prevention and treatment
Common side effects
- Major bleeding
- Minor bleeding
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (PHASE4)
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) (NA)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
- REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. (PHASE3)
- What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? (PHASE4)
- Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) (PHASE3)
- DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reduced dose of DOAC CI brief — competitive landscape report
- Reduced dose of DOAC updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI